Digital electron microscopic examination of human sural nerve biopsies

Journal of the Peripheral Nervous System

Volumn 8, Issue 4, 2003, Pages 260-270

  Sullivan, K A ^a   Brown, M S ^b   Harmon, L ^c   Greene, D A ^d  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Life Sciences Informatics Center   (United States)

^d Sanofi Synthelabo Inc   (United Kingdom)

Author keywords

Diabetes; Digital imaging; Electron microscopy; Human sural nerve; Neuropathy

Indexed keywords

ARTICLE; CAMERA; CELL DENSITY; CELL ULTRASTRUCTURE; COMPUTER ASSISTED DIAGNOSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIGITAL COMPUTER; ELECTRON MICROSCOPE; ELECTRON MICROSCOPY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MICROSCOPY; MICROVASCULATURE; MYELINATION; NERVE BIOPSY; NERVE FIBER; NERVE FIBER DEGENERATION; NERVE REGENERATION; PRIORITY JOURNAL; SCHWANN CELL; SURAL NERVE; TISSUE FIXATION;

AXONS; DIABETIC NEUROPATHIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSCOPY, ELECTRON; NERVE DEGENERATION; NERVE FIBERS, MYELINATED; SURAL NERVE;

EID: 0347354711     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1085-9489.2003.03030.x     Document Type: Article

References (47)

1. Albers JW, Brown MB, Sima AAF, Greene DA (1996a). Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Muscle Nerve 19:140-146.
2. Albers JW, Brown MB, Sima AAF, Greene DA (1996b). Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: The effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Neurology 46:85-91.
3. Black MM, Lasek RJ (1980). Slow components of axonal transport: two cytoskeletal networks. J Cell Biol 86:616-623.
4. Britland ST, Young RJ, Sharma AK, Clarke BF (1990). Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 39:898-908.
5. Cameron NE, Cotter MA (1995). Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 96:1159-1163.
6. Comi G, Fedele D, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, Negrin P, Santeusanio F, Maderna L, Italian Diabetic Neuropathy Committee (1999). The Italian multicentre study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. In: Clinical Neurophysiology: From Receptors to Perception (EEG Suppl. 50). Comi G, Lucking CH, Kimura J, Rossini PM (Eds). Elsevier Science, Cambridge, UK, pp 546-552.
7. Diemel LT, Brewster WJ, Fernyhough P, Tomlinson DR (1994). Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Brain Res Mol Brain Res 21:171-175.
8. 31P NMR spectroscopy study. Int J Biochem 26:759-767.
9. Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R (1986). Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 19:425-439.
10. Feldman EL, Stevens MJ, Greene DA (1994a). Treatment of diabetic neuropathy. In: Advances in Endocrinology and Metabolism. Mazzaferri EL, Bar RS, Kreisberg RA (Eds). Mosby Year Book, St Louis, MO, pp 393-428.
11. Feldman EL, Stevens MJ, Greene DA (1997). Pathogenesis of diabetic neuropathy. Clin Neurosci 4:365-370.
12. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA (1994b). A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17:1281-1289.
13. Garrett NE, Malcangio M, Dewhurst M, Tomlinson DR (1997). α-lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci Lett 222:191-194.
14. Greene DA, Arezzo JC, Brown MB (1999). Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 53:580-591.
15. Greene DA, Brown MB (1995). Validation of sural nerve fiber density and percent normal teased fibers as morphological endpoints in clinical trials of diabetic neuropathy. In: Diabetic Neuropathy: New Concepts and Insights. Hotta N, Greene DA, Ward JD, Sima AAF, Boulton AJM (Eds). Exerpta Medica, Elsevier, Cambridge, UK, pp 379-385.
16. Greene DA, Feldman EL, Stevens MJ, Sima AAF, Albers JW, Pfeifer MA (1997). Diabetic neuropathy. In: Diabetes Mellitus. Porte D Jr, Sherwin R (Eds). Appleton & Lange, Norwalk, CT, pp 1009-1076.
17. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Killen PD, Henry DN, Thomas T, Dananberg J, Lattimer SA (1993). Aldose reductase inhibitors: An approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 9:189-217.
18. Hellweg R, Hartung H-D (1990). Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 26:258-267.
19. Herman WH, Sinnock P, Brenner E, Brimberry JL, Langford D, Nakashima A, Sepe SJ, Teutsch SM, Mazze RS (1984). An epidemiologic model for diabetes mellitus: incidence, prevalence, and mortality. Diabetes Care 7:367-371.
20. Hotta N (1995). New approaches for treatment in diabetes: Aldose reductase inhibitors. Biomed Pharmacother 49:232-243.
21. Jacobs JM, Love S (1985). Qualitative and quantitative morphology of human sural nerve at different ages. Brain 108:897-924.
22. King RHM, Llewelyn JG, Thomas PK, Gilbey SG, Watkins PJ (1989). Diabetic neuropathy: Abnormalities of Schwann cell and perineurial basal laminae. Implications for diabetic vasculopathy. Neuropathol Appl Neurobiol 15:339-355.
23. Llewelyn JG, Gilbey SG, Thomas PK, King RHM, Muddle RJ, Watkins PJ (1991). Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. Brain 114:867-892.
24. Llewelyn JG, Thomas PK, Gilbey SG, Watkins PJ, Muddle JR (1988). Pattern of myelinated fibre loss in the sural nerve in neuropathy related to type 1 (insulin-dependent) diabetes. Diabetologia 31:162-167.
25. Love A, Cotter MA, Cameron NE (1996). Nerve function and regeneration in diabetic and galactosaemic rats: Antioxidant and metal chelator effects. Eur J Pharmacol 314:33-39.
26. Low PA, Nickander KK (1991). Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873-877.
27. Malik RA, Veves A, Walker D, Siddique I, Lye RH, Schady W, Boulton AJ (2001). Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol 101:367-374.
28. Nickander KK, McPhee BR, Low PA, Tritschler H (1996). α-lipoic acid: Antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 21:631-639.
29. Ochoa J, Mair WGP (1969). The normal sural nerve in man: ultrastructure and numbers of fibres and cells. Acta Neuropathol 13:197-216.
30. Perkins BA, Greene DA, Bril V (2001). Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy. Diabetes Care 24:748-752.
31. Pfeiffer A, Schatz H (1995). Diabetic microvascular complications and growth factors. Exp Clin Endocrinol 103:7-14.
32. Said G (1996). Diabetic neuropathy: an update. J Neurol 243:431-440.
33. Said G, Slama G, Selva J (1983). Progressive centripetal degeneration of axons in small fibre diabetic polyneuropathy. Brain 106:791-807.
34. Sima AAF, Bril V, Nathaniel V, McEwen TAJ, Brown MB, Lattimer SA, Greene DA (1988). Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 319:548-555.
35. Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B (1993a). Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. J Diabetes Complications 7:157-169.
36. Sima AAF, Stevens MJ, Feldman EL, Cherian PV, Greene DA (1993b). Animal models as tools for the testing of preventive and therapeutic measures in diabetic neuropathy. In: Lessons from Animal Diabetes IV. Shafrir E (Ed). Smith-Gordon, London, pp 177-191.
37. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 94:853-859.
38. Stevens MJ, Feldman EL, Funnell MM, Sima AAF, Greene DA (1993b). Optimal methods for detecting early neuropathy and its progression. In: Diabetes Forum IV Concepts for the Ideal Diabetes Clinic. Mogensen CE, Standl E (Eds). pp 315-332.
39. Stevens MJ, Lattimer SA, Feldman EL, Helton ED, Millington DS, Sima AAF, Greene DA (1996). Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na, K-ATPase activity and motor conduction velocity in the streptozotocin-diabetic rat. Metabolism 45:865-872.
40. Stevens EJ, Lockett MJ, Carrington AL, Tomlinson DR (1993a). Essential fatty acid treatment prevents nerve ischaemia and associated conduction anomalies in rats with experimental diabetes mellitus. Diabetologia 36:397-401.
41. Sundkvist G, Dahlin LB, Nilsson H, Eriksson KF, Lindgarde F, Rosen I, Lattimer SA, Sima AAF, Sullivan K, Greene DA (2000). Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance. Diabet Med 17:259-268.
42. Tomlinson DR, Mayer JH (1984). Defects of axonal transport in diabetes mellitus-a possible contribution to the aetiology of diabetic neuropathy. J Auton Pharmacol 4:59-72.
43. Vogt RC (1996). Robust extraction of axon fibers from large-scale electron micrograph mosaics. International Symposium on Mathematical Morphology.
44. Vogt RC, Trenkle JM, Harmon LA (1996). Mosaic construction, processing and review of very large electron micrograph composites. International Symposium on Optical Science, Engineering, and Instrumentation.
45. Whitworth IH, Terenghi G, Green CJ, Brown RA, Stevens E, Tomlinson DR (1995). Targeted delivery of nerve growth factor via fibronectin conduits assists nerve regeneration in control and diabetic rats. Eur J Neurosci 7:2220-2225.
46. Wolf SP (1993). Transition metals and oxidative stress in the complications of diabetes. In: The Role of Anti-Oxidants in Diabetes Mellitus. Gries FA, Wessels K (Eds). pmi-Verlags-grupe, London, pp 82-101.
47. Zenobi PD, Holzmann P, Glatz Y, Riesen WF, Froesch ER (1993). Improvement of lipid profile in Type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia 36:465-469.